Introduction
The -catecholamines of clinical interest, noradrenaline, adrenaline, and dopamine, are simple dihydroxyphenylamines which differ in their side chain structure. Dopamine is formed by the decarboxylation of dihydroxyphenylalanine (DOPA) --and is in turn hydroxylated to produce noradrenaline, which is then methylated to produce adrenaline. All three are important central nervous system neurotransmitters, with adrenaline, produced from the adrenal medulla, having an additional role as a circulating hormone.
As well as sharing a common synthetic pathway they are all degraded by a mixture of side chain oxidation and o-methylation of the hydroxyl groups on the ring. If metabolism is complete this will produce 4-hydroxy-3-methoxymandelic acid (HMMA), commonly called vanillyl mandelic acid (VMA), from both noradrenaline and adrenaline, and homovanillic acid (HVA), from dopamine. If o-methylation of the parent compound alone occurs, this will yield normetadrenaline, metadrenaline, and 3-methoxytyramine from noradrenaline, adrenaline, and dopamine, respectively. The catecholamines and some of their o-methylated derivatives are excreted as glucuronide and sulphate conjugates in the urine.
Increased urinary excretion of unconjugated catecholamines (noradrenaline, adrenaline, and dopamine) or their main metabolites, HMMA, HVA, and the methoxycatecholamines (metadrenaline and normetadrenaline) have been used as a tumour marker for neuroblastoma in children and phaeochromocytoma in adults. Both these tumours arise from primitive neural crest tissue and have the capacity to secrete catecholamines directly into the circulation. Increased urinary catecholamine excretion and high plasma catecholamine concentrations have also been used to monitor "stress" under different environmental conditions. Phaeochromocytoma There are few clinical conditions in which the responsibility for diagnosis depends more on the laboratory than phaeocnromocytoma. This is a rare catecholamine-secreting tumour of neural crest origin that characteristically produces episodes of hypertension, severe headaches, and sweating. Patients with phaeochromocytoma more commonly have sustained rather than intermittent hypertension. Less commonly they may present with one or more of the following: loss of consciousness; and chest or abdominal pain, or both. Undiagnosed, the excess circulating catecholamines may produce cardiac muscle necrosis, with sudden death precipitated by surgery or pregnancy remaining a common mode of presentation.' To add to our embarrassment 90% of these histologically benign tumours can be removed and do not recur after surgery. Unfortunately, most clinicians limit investigation to young patients with intermittent or uncontrollable hypertension. In fact phaeochromocytomas have been found in subjects from 9 months to 90 years of age and are more common in older (50 years and over) than younger subjects. '2 The detection of this rare disease is not helped by laboratories having to rely on outmoded and uncontrolled analytical methods. Clinicians should be encouraged to look for this curable disorder and not be put off by unrealistic demands that all medication be discontinued and stringent dietary restrictions enforced. Once considered, the diagnosis of phaeochromocytoma could be made by proving increased release of the catecholamines noradrenaline and adrenaline into the circulation and their excretion with their metabolites in the urine.
Plasma catecholamine concentrations can now be more easily measured. I would recommend that free catecholamines be measured in 24 hour urine collections for the following reasons: (1) they are more stable in acid urine than plasma; (ii) catecholamines are present in higher concentrations in the urine and are therefore easier to measure than in plasma, which must be rapidly separated, frozen, and stored at -20'C; and (iii) plasma catecholamine concentrations provide single point readings which vary with the immediate physiological and pathological condition of the patient, whereas urinary catecholamine excretion provides an integrated measurement This Broadsheet has been prepared by the authors at the invitation of the Association of Clinical Pathologists who reserve the copyright. Further copies of this Broadsheet may be obtainedfrom theof catecholamine release and is theoretically more valid.
Measurement of plasma catecholamine concentration does have a place in the following circumstances: (i) in the anuric patient; (ii) when there is difficulty in obtaining urine specimens-for example, in some children or very uncooperative patients; (iii) when drugs or other substances interfere with urine assays; and (iv) rarely, to help localise a phaeochromocytoma.
As well as the parent compounds, noradrenaline, adrenaline, and dopamine, there are several catecholamine metabolites which can be measured in the urine. These include metadrenaline and normetadrenaline, often combined in one asay and referred to as total metadrenalines. HMMA was the most commonly used analyte in a United Kingdom survey done for the Catecholamine External Quality Assessment Scheme,3 though experience has shown this analyte to be less reliable than metadrenalines.4 HVA, an end product of dopamine metabolism, will theoretically be more appropriate for the diagnosis of neuroblastoma than phaeochromocytoma.
Experience in running an external urinary catecholamine quality assessment scheme has highlighted many deficiencies in laboratory performance.' These can be attributed to: (i) the slavish acceptance of previously reported recoveries; (ii) the failure to put primary standards through the same analytical process as patients' samples; (iii) the infrequency with which the assay is carried out; (iv) the rarity of positive results and the delegation of the assay to less experienced laboratory staff.
While most phaeochromocytomas (about 90%) occur in the adrenal glands, they may be found in nests of sympathetic nervous tissue anywhere from the neck to the groin. Adrenal tumours may be identified by computed tomography and ultrasound examination. Those laboratories with a small workload un-able to justify the expense of the essential equipment or lacking the experienced staff for these techniques, should consider sending their specimens to an appropriate laboratory for analysis.
The first method uses a simple initial alumina extraction but depends for specificity on HPLC separation and sensitive serial electrochemical detectors. Our laboratory is in the process of adopting a new commercially available sample preparation method (ASTED) which will be covered briefly.
With urinary noradrenaline excretion used as a marker to identify the patient with phaeochromocytoma and urinary dopamine excretion used to recognise children with neuroblastomas, the measurement of urinary free catecholamine excretion using HPLC would, theoretically, provide a complete service. Because the available biochemical markers of neuroblastoma lack sensitivity, I have included HPLC methods for the measurement of urinary HVA and HMMA excretion. This would identify those neuroblastomas excreting predominantly catecholamine metabolites.
Measurement of urinary free catecholamines using HPLC with electrochemical detection PRINCIPLE Many HPLC methods have been described for the measurement of urinary catecholamines. The following procedure is used to measure noradrenaline, adrenaline, and dopamine in both urine and plasma. Catecholamines are adsorbed from the urine with activated alumina, eluted with acid, separated by reverse phase ion-pair chromatography and measured by electrochemical detection. Ascorbic acid is used as an antioxidant to prevent catecholamine degradation8 while an autoinjector permits unattended batch analysis of many samples.
Measurement is based on the ability of catecholamines to be reversibly oxidised to their corresponding o-quinones. In the method to be described three electrodes, set at different potentials and arranged in series, cause sequential oxidation and reduction which screens out interfering compounds. Less selective detection systems will require more extensive sample preparation.
COLLECTION OF URINE SPECIMENS
Collect a 24 hour specimen ofurine into a bottle containing 50 ml of 500 mmol/l sulphuric acid (or 10 ml concentrated HCl) and measure the volume. Store an aliquot at 4'C or at -20'C if analysis is delayed for some months. I have found that, provided the specimens are acidified (pH < 2), they keep for months and may be transported by ordinary post to other centres for analysis. (Plasma catecholamines are more labile and samples must be kept frozen until analysed). Dissolve 15-8 g of citric acid (monohydrate), 7 02 g of Na2HPO4 (anhydrous), 0 074 g disodium EDTA and 0-880 g 1-heptanesulphonic acid (sodium salt, Sigma) in 700 ml of distilled water. Check that the pH is 3-2 and make the final volume up to 1 litre with distilled water. Add 110 ml of methanol and 40 ml of acetonitrile (both HPLC grade) and mix. Before use, the mobile phase must be filtered and degassed under vacuum using a 0 2 p membrane. ("noradrenaline"; Sigma); 33 3 mg epinephrine bitartrate ("adrenaline"; Sigma); 18 9 mg 3-dydroxytyramine ("dopamine"; Sigma); 22 0 mg 3,4-dihydroxybenzylamine (Sigma). These solutions may be stored at 4°C for up to six months. 6 Intermediate standards: 20 pmol/l are prepared by diluting 2 ml of each stock standard individually to 100 ml with 0-02 mol/l HCl. These can be stored for up to three months at 4'C. 7 Working standards: prepared from the intermediate standards immediately before each assay and not reused (unless stored at -20°C). PROCEDURE During the extraction procedure described below, all test tubes, reagents, and samples should be kept at 4°C on a cold tray. To 4 ml polystyrene tubes (Sartstedt) add: (1) 1-5 ml distilled water; (2) 0-1 ml ascorbic acid solution; (3) 0-2 ml 100 nmol/l DHBA in 0-02 mol/l HCl; (4) Most phaeochromocytomas secrete noradrenaline. The findings ofhigh urinary adrenaline excretion with normal urinary noradrenaline excretion should lead you to suspect some other cause, such as severe "stress" or a neurological disorder. One patient with persistently raised urinary adrenaline excretion was found at necropsy to have an infiltrative malignancy of his brain and spinal cord, and no phaeochromocytoma.'0 Nevertheless, the presence of persistently raised urinary catecholamine excretion (adrenaline or noradrenaline) does justify minimum investigation such as adrenal ultrasound examination, computed tomography scan, and an MIBG scan.
If biochemical tests remain positive and attempts to localise the tumour fail catecholamine release as a result of stress may be suspected. A reduction in catecholamine excretion induced by sleep or clonidine, or both, would suport this diagnosis." In practice this has not been a major diagnostic problem. Failure to localise a tumour precludes surgery anyway and the patient must be managed medically before repeating radiographic localisation.
I have heard of only one false negative, urine free catecholamine excretion result (using HPLC and electrochemical detection) in an adult with a phaeochromcytoma (Sinclair D, Shenkin A, personal communication). Unfortunately, urine metabolites were not measured.
Interpretation of urine catecholamines and their metabolite excretion in children is difficult, because of physiological variation of excretion rate with age and because it is not always possible to obtain 24 hours urine collections. The biochemical findings in 174 patients with neuroblastoma have been reported. 6 Simple assays for dopamine alone were not generally available throughout the 16 year period required to collect this large number of cases.7 These workers found that total catecholamines (the sum of adrenaline, noradrenaline, and dopamine) were marginally more sensitive (84%) than HMMA (78%) in diagnosing neuroblastomas, with virtually identical specificities. They provide an age related reference range for children, expressing results per mol of creatinine, for the total catecholamines, total metadrenalines, and HMMA. 6 The combination of total catecholamine and HMMA excretion increased the sensitivity to 98-9%. It is important to know whether dopamine excretion alone would be a better discriminator of neuroblastomas than total catecholamine excretion.
Our laboratory (unpublished data) has measured the individual catecholamine excretion per mole of creatinine in 46 paediatric inpatients, 482 healthy school children (aged 5-16), and 17 outpatients under the age of 5. Results (table) confirm that catecholamine excretion rates fall from high values under the age of 5 years to approach adult values by the age of 10. None of these children had a phaeochromocytoma and only five had a neuroblastoma. There was an overlap in both urine noradrenaline and adrenaline excretion between unaffected children and those with neuroblastoma. Urine dopamine excretion, however, was a better discriminator between the "normals" and our small series of patients with neuroblastomas. The highest dopamine excretion rate in an unaffected child was 1500 pmol/mol creatinine, well below the lowest dopamine excretion rate of 5000 ,umol/ mol creatinine in one of the children with a neuroblastoma. A larger series may blur this encouraging difference.
I have had few problems with the above assay despite the broad range of medication our patients receive, such as paracetamol, Aldomet, and labetalol which are known to interfere with catecholamine assays.'2
The ASTED modification for the measurement of urinary free catecholamine5 PRINCIPLE In more than 95% of urine samples we process sample preparation with a simple alumina extraction is sufficient to avoid assay interference. Specificity is preserved by the sophisticated HPLC separation, supported by serial electrochemical oxidation and reduction described above. Interfering peaks found in the occasional urine specimen have been managed by combining the alumina extraction with a second solid phase extraction or measuring the patient's plasma catecholamine concentration.
To further reduce interference and simplify the urinary catecholamine assay we are testing the ASTED system. This method has been published'3 and is commercially available as an ASTED unit from Gilson Medical Electronics (Villiers-le-Bel, France). ASTED is the acronym for "automated sequential trace enrichment of dialysate," an automated sample preparation technique. It involves dialysis of the sample and concentration of the analyte on a suitably packed stainless steel trace enrichment cartridge (TEC) which replaces the loop on the Rheodyne injection valve.
For the catecholamine assay, the urine samples are not dialysed but are simply concentrated on the packing material, 10 Mix and inject 25 Ml on to the column.
CHROMATOGRAPHY
Set the mobile flow rate at 1-0 ml/minute and monitor the column effluent at + 0-67 volts using a 0-100 nA sensitivity range and filter setting of 0 5 second. The retention times for HMMA, 5-HIAA, HVA and IsoVA (internal standard) are about 2-5, 10, 15 and 17 5 minutes, respectively. Measure the relevant peak heights.
CALCULATION
Excretion of metabolite = U x 100 x V/(S -10/11 x U) ymol/24 hours where U and S are the analyte to internal standard peak height ratios of the "unspiked" and "spiked" samples, respectively, and V is the 24 hour urine volume in litres.
INTERPRETATION
The adult reference range for 24 hour urine excretion of HMMA, 5-HIAA, and HVA are <35, <50, and <40 Mmol/24 hours, respectively. As with the measurement ofurinary free catecholamines, major errors are caused by unacidified urine and inaccurate urine collection. Discard all urine specimens with a pH of more than 4-0. Urine creatinine should be measured to assess the completeness of the urine collection.
The finding ofincreased urine catecholamine metabolite excretion makes it imperative that the clinician search for a phaeochromocytoma or neuroblastoma. If there is any doubt about the validity ofthe assay it should be repeated on a fresh urine collection made after all drugs have been discontinued. 
